Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
EphA2-binding Peptide and Composition Patent Application
The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.
Macrocyclic CFTR Modulators for Cystic Fibrosis
USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.
Peptide Compositions Targeting β-Catenin for Treatment of Endometriosis
USPTO published patent application US20260098059A1 for peptide compositions targeting β-catenin for treatment of endometriosis. The application covers peptides that bind β-catenin and prevent nuclear translocation, modulating the canonical Wnt pathway. Filed October 10, 2025 under Application No. 19355926. Patent rights are not yet granted; applicants seeking to develop similar therapies should review the published claims for freedom-to-operate considerations.
Ovarian Cancer Diagnostic Marker, Urteste S.A
Ovarian Cancer Diagnostic Marker, Urteste S.A
Cancer Treatment Patent Using Quinoline Derivative and Antibody
The USPTO published patent application US20260097030A1 on April 9, 2026, disclosing a therapeutic combination of a quinoline derivative and an antibody for treating cancer, specifically lung and liver tumors. The application names 14 inventors and was filed on April 11, 2025. This publication makes the application publicly available but does not grant any enforceable patent rights.
MPN Treatment Methods with Therapeutic Compounds
USPTO published patent application US20260097028A1 for therapeutic methods treating myeloproliferative neoplasms (MPN) including polycythemia vera, essential thrombocythemia, and myelofibrosis. The application covers combination therapies using compounds of Formula (I) or Formula (II) with JAK inhibitors, IDH inhibitors, PD-1/PD-L1/PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, or nucleoside analogs. Filed February 18, 2025, application number 19055807.
Proton Pump Inhibitors for Inhibition of Aortic Valve Calcification
USPTO published patent application US20260097026A1 for the use of proton pump inhibitors including prazole compounds to inhibit calcification of aortic valves, treating aortic sclerosis and stenosis. The application was filed on October 3, 2023, with inventors Arsenii Zabirnyk, Ingvar Jarle Vaage, and Kåre-Olav Stensløkken. The invention is classified under CPC codes A61K 31/4439 and A61P 9/10.
Plant-Based DHA and Berberine Compositions for Treating Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease
The USPTO published patent application US20260097024A1, filed October 7, 2025, covering compositions and methods for treating obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease using synergistically effective amounts of plant-based DHA and berberine. Inventors are Roger Catarino and William Kuhne. The application has been made publicly available as part of the 18-month patent publication process.
Neuroplasticity Treatment Method with Neurostimulation and Dopamine Agonist for Depression
USPTO published patent application US20260097224A1 disclosing a method for treating neuroplasticity-related conditions by administering a dopamine receptor agonist combined with neuroplasticity-modulating drugs prior to or simultaneously with targeted energy-based neurostimulation, repeated within one day. The preferred embodiment targets depression using transcranial magnetic stimulation. Inventors are Donald A. Vaughn and Jonathan A.S. Downar, with application number 19274159 filed July 18, 2025.
Modified-Release Minoxidil Compositions and Methods for Hair Loss Treatment
The USPTO published patent application US20260097035A1 filed by inventor Reid Waldman on December 10, 2025, covering modified-release minoxidil compositions for treating hair loss. The application discloses pharmaceutical formulations for oral administration of modified-release minoxidil and methods of using the compositions for hair loss treatment.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
647 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.